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Edited by Gianni CesareniAbstract We have previously shown that ﬁbroblast growth
factor receptor 2 (FGFR2) plays an important role in gastric
carcinogenesis. In this study, we have used a diﬀerential display
approach to identify basic ﬁbroblast growth factor (bFGF)-
inducible genes in gastric cancer cells. Here, we report that one
of these genes is predicted to encode a RING ﬁnger protein,
designated FIGC. The FIGC gene was found to encode a
polypeptide of 381 amino acids with a novel RING ﬁnger module
at the NH2-terminus and the COOH-terminal proline-rich
region. Using an in vitro ubiquitination assay with recombinant
protein, we demonstrate that FIGC has intrinsic E3 ubiquitin
ligase activity and promotes ubiquitination. Our data indicate
that FIGC upregulation in response to bFGF in gastric cancer
might be implicated in carcinogenesis through dysregulation of
growth modulator.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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receptor 21. Introduction
Fibroblast growth factors (FGFs) are mitogens that regulate
a multitude of cellular processes, including cellular prolifera-
tion, cellular diﬀerentiation, wound repair, angiogenesis, and
carcinogenesis [1–6]. In addition, overexpression of FGF in
various cell lines leads to phenotypic transformation [7–9].
FGFs stimulate cellular responses by binding to cell surface
tyrosine kinase receptors [10]. Fibroblast growth factor re-
ceptors (FGFRs) encode a transmembrane tyrosine kinase
receptor involved in signaling via interaction with the family of
FGFs. Four structurally related receptors, designated isoforms
of the FGFR-1, -2, -3, and -4, have been identiﬁed [11]. Basic
FGF can bind with high aﬃnity to the FGFR family members
identiﬁed to date [12]. Although it is known that ligand
binding stimulates FGF receptor tyrosine autophosphoryla-
tion and dimerization [12–14], the subsequent biochemical* Fax: +82-32-882-1877.
E-mail address: juhjang@inha.ac.kr (J.-H. Jang).
Abbreviations: bFGF, basic ﬁbroblast growth factor; FGF, ﬁbroblast
growth factor; FGFR, FGF receptor; PBS, phosphate-buﬀered saline;
E1, ubiquitin-activating enzyme; E2, ubiquitin-conjugating enzyme;
E3, ubiquitin-protein ligase; SDS–PAGE, sodium dodecyl sulfate–
polyacrylamide gel electrophoresis.
0014-5793/$22.00  2004 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2004.10.071pathway responsible for FGF mitogenic signal transduction
has not been elucidated.
We have previously shown that FGFR2 plays an important
role in gastric carcinogenesis [6]. However, the mechanisms for
the oncogenic activity of FGFs have not been identiﬁed. To
further elucidate mechanisms of FGFs action, we have at-
tempted to identify novel genes involved in the events of FGF-
triggered signals using PCR-based diﬀerential display [15]. We
are presently identifying and characterizing novel bFGF-in-
ducible genes in gastric cancer cell line, SNU-16, in order to
gain further insight into the role of bFGF in gastric cancer. In
this paper, we describe the cloning and characterization of a
cDNA representing a novel gene, FIGC, whose steady-state
levels increased in response to bFGF.
Here, we describe a gene regulated by bFGF that encodes a
predicted protein of 381 amino acids, which we named FIGC.
We present evidence that FIGC contains a RING ﬁnger do-
main and has intrinsic E3 ubiquitin ligase activity. The RING
motif consists of a series of eight conserved cysteines and
histidines, which bind two zinc atoms and form a structure of
‘‘crossbraced’’ rings. Recent studies have shown that RING
ﬁnger proteins play critical roles in mediating the transfer of
ubiquitin to heterologous substrates as well as to the RING
ﬁnger themselves [15–18]. Ubiquitin conjugation (ubiquitina-
tion) is recognized as a multifunctional signaling mechanism.
Polyubiquitination is a signal for destruction of proteins by
26S proteasomes [19,20]. By serving as a signal for speciﬁc
cellular protein degradation, ubiquitination plays a critical role
in physiological regulation of many cellular processes. Hence,
FIGC upregulation in response to bFGF in gastric cancer
might be implicated in carcinogenesis through dysregulation of
growth modulator.2. Materials and methods
2.1. Cell culture
Human gastric cancer cell line, SNU-16 (Korean Cell Line Bank),
was grown at 37 C in RPMI 1640 (Life Technologies, Inc.) supple-
mented with 10% (v/v) heat-inactivated bovine calf serum (Life
Technologies, Inc.) and a 1:100 dilution of a penicillin–streptomycin–
fungizone solution (Life Technologies, Inc.). Subconﬂuent cells were
incubated for 24 h in the above medium containing a reduced serum
concentration (0.5%) to induce a relatively quiescent cell population.
Cells were then either left untreated or treated for various times with
0.5% calf serum supplemented with 20 ng/ml recombinant human
bFGF (Promega).
2.2. RNA isolation and cDNA synthesis
The TRI REAGENT kit (Life Technologies, Inc.) was used to
isolate total RNA from cell lines. The ﬁrst-strand synthesis ofblished by Elsevier B.V. All rights reserved.
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out with 1st Strand cDNA Synthesis Kit (Boehringer–Mannheim).
2.3. cDNA cloning and sequencing
GeneFishing kits (Seegene) were used for diﬀerential display
following the manufacturer’s instructions. The PCR or RACE
products were cloned into TA cloning vector and then sequenced
with T7 or SP6 promoter primers using DyeDeoxy terminators
(Applied Biosystems) and an ABI 373 DNA sequencer (Applied
Biosystems). The full-length cDNA sequence of FIGC was obtained
using a 50-RACE and 30-RACE kit (Clontech) with human brain
cDNA library (Clontech). Sequence identity was conﬁrmed by
BLAST searches on the combined GenBank/EMBL non-redundant
(nr) and expressed sequence tag libraries (dbEST), accessed through
the National Center for Biotechnology Information homepage
(http://www.ncbi.nlm.nih.gov/). Protein homologies were traced us-
ing the Blitz algorithm run at the EMBL/European Bioinformatics
Institute (http://www.ebi.ac.uk) and functional protein domains
were traced using the BLOCKS WWW-server (http://
www.blocks.fhcrc.org/).
2.4. Northern blot analysis
Northern blot analysis was carried out using a standard procedure.
Cells were washed twice with ice-cold phosphate-buﬀered saline
(PBS). Total RNA was isolated with the Trizol (Life Technologies,
Inc.) one step total RNA isolation method according to the manu-
facturer’s instructions. Brieﬂy, 10 lg of total RNA was size-frac-
tionated by gel electrophoresis in 1% agarose/6% formaldehyde gels
and transferred onto the nitrocellulose membrane by a capillary blot
method. Northern blots were prehybridized at 42 C for 2 h with a
solution containing 50% formamide, 5 SSC, 50 mM Tris–HCl, pH
7.5, 0.1% sodium pyrophosphate, 1% SDS, 0.2% polyvinylpyrroli-
done, 0.2% Ficoll, 5 mM EDTA, 100 lg/ml denatured salmon sperm
DNA, and 0.2% bovine serum albumin before hybridizing with either
32P-labeled FIGC cDNA probes (106 cpm/ml) in the same solution
for overnight. The hybridized membranes were exposed to Fuji RX
X-ray ﬁlm at )70 C.
Multiple tissue poly(a)+ RNA blots were purchased from Clontech
(Palo Alto, CA) and hybridized according to the enclosed protocols.
The ClonTech Multiple Tissue Northern blots contained 2 lg of ol-
igo(dT)-puriﬁed mRNA from diﬀerent speciﬁc normal human tissues.
2.5. In vitro ubiquitination assay
Ubiquitination assays were carried out by adding GST-FIGC (400
ng), rabbit E1 (50 ng, Calbiochem), UbcH5b (100 ng, Calbiochem),
His-tagged ubiquitin (5 lM, Sigma) and 2 ll of bacterial lysate in
ubiquitination buﬀer containing 50 mM Tris–HCl (pH 7.5), 5 mM
MgCl2, 2 mM ATP, and 2 mM dithiothreitol (DTT). The reaction
mixture (30 ll) was incubated at 30 C for 2 h. The reactions were
stopped with 2 SDS sample buﬀer, resolved on 10% SDS–PAGE and
subjected to immunoblotting with an anti-His antibody (Santa Cruz
Biotechnology).Fig. 1. Predicted amino acid sequence for human FIGC. The deduced ami
initiation methionine. Six conserved amino acids in the RING ﬁnger domain
underlined.2.6. GenBank accession numbers
p300 (Homo sapiens), Q09472; Utropin (Dystrophin-related protein
1, H. sapiens), CREB-binding protein-1 (Caenorhabditis elegans),
P34545; Dystrophin-related protein 2 (H. sapiens), Q13474.3. Results
3.1. Identiﬁcation and sequence analysis of FIGC,
a FGF-inducible gene
A partial cDNA fragment induced by bFGF was isolated by
diﬀerential display using mRNAs from the bFGF-stimulated
and unstimulated human gastric cancer cell line, SNU-16.
Ampliﬁcation products were displayed using agarose gel elec-
trophoresis and ethidium bromide staining. However, DNA
fragments, about 600 bp in size, were ampliﬁed to a greater
degree when cDNA representing the RNA isolated from cells
treated with bFGF was used as template. The 600-bp fragment
was excised from the gel, reampliﬁed, and subcloned. Nucle-
otide sequence analysis of the isolated cDNA and comparison
with the GenBank data base indicated it to be a novel gene.
Subsequent characterization of this gene in our laboratory
revealed that it is induced by bFGF. Therefore, it has been
designated FIGC (for bFGF-induced in gastric cancer).
For searching the full-length of the partial cDNAs, 5 RACE
was performed by using both strands of the FIGC cDNA in-
sert, which were sequenced as described in Section 2. The
nucleotide sequence contained a long open reading frame en-
coding a protein of 381 amino acids with a predicted molecular
mass of 42 kDa (Fig. 1). The cDNA clone contained a 375-
nucleotide 30-untranslated region with a consensus polyade-
nylation signal (the DDBJ/EMBL/GenBank Accession No.
AB083199 and Swiss-Prot Accession No. Q9P0J7).
Northern blot analysis of RNA isolated from serum-starved
or bFGF-treated SNU-16 cells was then performed to conﬁrm
the diﬀerential display results, indicating that FIGC was an
bFGF-inducible gene. The FIGC transcript was upregulated
following bFGF stimulation. FIGC RNA was increased by 4
h, was maximal by 8 h, and this high level was maintained
throughout the experiment (Fig. 2).
3.2. FIGC contains a RING ﬁnger domain
A search of GenBank protein data bases showed that this
protein has a novel RING ﬁnger motif at the NH2-terminusno acid sequence is shown and numbered starting at the presumable
(d) are shown below amino acid sequence and proline-rich regions are
Fig. 2. Eﬀect of bFGF on FIGC mRNA levels. Serum-starved cells
were either left untreated or treated with bFGF (10 ng/ml) for the
times indicated. Total RNA (10 lg) was subjected to Northern blot
analysis as described under Section 2. b-Actin was used as an internal
standard for quantiﬁcation of total RNA in each lane of the gel.
Fig. 4. Ubiquitination of FIGC. GST-FIGC was evaluated for E3
activity in the presence of His-tagged Ub as indicated. Following the
ubiquitination reaction, the samples were subjected to SDS–PAGE
and immunoblotting with His antibody to reveal ubiquitinated prod-
ucts. An asterisk marks the non-speciﬁc bands observed in all lanes.
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the C3HC4 RING ﬁngers and C3H2C3 RING ﬁngers [21]. In
this study, FIGC, p300, Utrophin, Creb-binding protein-1
(CBP-1), and Dystrophin-related protein2 (Drp2) were classi-
ﬁed into the novel subclass of RING ﬁngers, which contains
distinguished consensus sequence CX2C(7-11)CX2CXA5-
CX2CX(5-9)HX(1-3)H (XA: acidic residues) from C3HC4
RING ﬁngers and C3H2C3 RING ﬁngers. All eukaryotes
encode C6H2-type RING proteins and such proteins were
represented in some species by several distinct isolates, indi-
cating that the C6H2-type RING ﬁnger unit deﬁnes an evo-
lutionarily highly conserved module (Fig. 3).
3.3. FIGC has ubiquitin-protein ligase activity
The RING ﬁnger motif is essential for the E3 activity. It has
been shown that the RING ﬁnger motif is required for theFig. 3. Schematic presentation of FIGC cDNA. (A) The coding regions are d
element (hatched box), and proline-rich region (gray box) in ORF are shown.
amino acid sequences of the C6H2 regions of FIGC and proteins containin
Putative metal-ligating residues (based on their conservation across all specie
RING ﬁnger is separated by an acidic spacer element (d). (C) C6H2-type R
ﬁnger.ubiquitin ligase activity for almost all the RING ﬁnger-con-
taining E3 enzymes. E3 accelerates the ubiquitination of its
substrate and sometimes E3 is itself ubiquitinated. Therefore,
the in vitro demonstration of substrate-independent auto-
ubiquitination is a good indication of the E3 activity. We de-
cided to examine whether FIGC has intrinsic ubiquitin-protein
ligase activity. To determine if FIGC has intrinsic ubiquitin-
protein ligase activity, we used an in vitro ubiquitination assay.
Aﬃnity puriﬁed GST-FIGC was incubated at 30 C with ATP,
His-tagged ubiquitin, and the bacterial lysates containing re-
combinant E1 and E2, and subjected to immunoblotting with
the anti-His antibody. As shown in Fig. 4, FIGC-mediated
ubiquitination was readily detected and was dependent on theepicted as an open box. RING ﬁnger domain (closed box), acid spacer
(B) Amino acid alignments of RING ﬁnger modules. Alignments of the
g FIGC-type zinc ﬁngers from a range of diﬀerent species are shown.
s) are highlighted in bold, and the consensus sequence is boxed. C6H2
ING ﬁnger consensus sequence and schematic presentation of RING
Fig. 5. Northern blot analysis of FIGC. Polyadenylated RNA from diﬀerent tissues on Northern blots was hybridized with a probe of full-length
cDNA. The arrow indicates the hybridizing band of approximately 2 and 1 kb.
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had the ubiquitin-protein ligase activity.3.4. Messenger RNA expression of FIGC in human organs
We next used Northern blot analysis to examine the tissue
distribution of FIGC mRNA. The FIGC gene was expressed in
human spleen, small intestine, ovary, peripheral blood, lung,
skeletal muscle, kidney, and pancreas, but was expressed at a
low level in the thymus, prostate, testis, colon, heart, brain,
placenta, and liver (Fig. 5).
To date, very few FGF response genes have been identiﬁed
[22]. Accordingly, we have utilized the diﬀerential display
methodology to isolate cDNAs representing such genes [23–
25]. In this paper, we describe the cloning and characterization
of a cDNA representing a novel gene, FIGC, whose steady-
state levels increased in response to bFGF. We show that the
FIGC protein has a novel C6H2-type RING ﬁnger domain at
the NH2-terminal region. To date, all characterized examples
of RING ﬁnger domains have been shown to possess E3 ligase
activity in vitro [21,26,27]. For some RING ﬁnger E3 ligases, it
was found that the RING ﬁnger structure binds the E2.
However, the exact mechanism by which the RING ﬁnger
containing E3 ligase catalyzes the transfer of ubiquitin to the
target proteins is yet unknown.
Although we have shown here that FIGC is polyubiquiti-
nated, probably signifying that it functions as an E3 ligase, we
cannot exclude other potential functions. Indeed, accumulat-
ing evidence has shown that RING ﬁngers have other cellular
functions. Zinc-coordinated RING ﬁngers have been shown to
mediate dimerization of proteins such as BARD1 and BRCA1,
Mdm2 and MdmX, and constitutive photomorphogenic pro-
tein 1and CIP8 [28–30]. Recently, a RING ﬁnger-like domain,
the FYVE domain, has been determined to bind speciﬁcally
phosphatidylinositol 3-phosphate [31]. The FYVE domain
contains a highly conserved motif that provides speciﬁcity for
binding to phosphatidylinositol 3-phosphate. Moreover, in the
case of Mdm2 the RING ﬁnger not only mediates ubiquiti-
nation for p53 but also binds to RNA [32].
FGFR represents an important example of a single gene that
causes diﬀerent human developmental and tumoral diseases.
We have previously identiﬁed two identical mutations inFGFR2 that cause craniosynostosis syndromes, Crouzon,
Apert, and Pfeiﬀer in gastric cancers [6]. The ﬁnding of iden-
tical mutations in skeletal dysplasias and gastric cancers is the
ﬁrst evidence for the involvement of the somatic mutations of
FGFR2 in gastric cancer, and suggests that a similar mecha-
nism of ligand-independent constitutive activation of the
FGFR2 product is responsible for both diseases. Thus, the
identiﬁcation of substrates of FIGC in response to bFGF sig-
nal should greatly advance our understanding of the tumori-
genic activity of FGFs. Further studies are in progress to
identify and characterize proteins interacting with FIGC and
to knock out the FIGC gene.
Thus, upregulation of FIGC might aﬀect the turn-over rates
of its substrates of ubiquitination and might lead to dysregu-
lation of negative regulators of tumor development in gastric
cancer. Although the substrates of FIGC remain to be eluci-
dated, upregulation of FIGC in response to bFGF in gastric
cancer might be implicated in carcinogenesis through dysre-
gulation of growth modulator. Identiﬁcation of its substrates
may provide a potential new target for assessing the tumori-
genic activity of FIGC or FGFs in tumor therapy.References
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